文献速递新生儿儿童感染

黏菌素治疗多重耐药新生儿败血症的疗效:巴基斯坦卡拉奇三级医疗中心经验

Efficacy of colistin in multidrug-resistant neonatal sepsis: experience from a tertiary care center in Karachi, Pakistan.
PubMed 文献 · Arch Dis Child · 2020-03-20

该回顾性记录回顾研究了2015年6月至2018年6月期间在巴基斯坦卡拉奇Aga Khan大学医院新生儿重症监护室收治的153例接受黏菌素治疗的新生儿败血症患儿,其中120例为培养证实的败血症,93例为多重耐药革兰阴性菌(MDR-GNB)感染。结果显示111例(72.5%)存活出院,82.6%实现微生物清除;黏菌素敏感菌感染和早期启动黏菌素治疗与更高生存率相关。不良反应包括肾毒性5.2%、惊厥13.7%和电解质紊乱18.3%。

要点

  • 黏菌素治疗多重耐药革兰阴性菌新生儿败血症与存活相关,72.5%患儿存活出院。
  • 黏菌素敏感菌感染(AOR=3.2)和早期启动治疗(AOR=7.2)与更高生存率相关。
  • 不良反应发生率中等:肾毒性5.2%、惊厥13.7%、电解质紊乱18.3%。

核心结论

  • 黏菌素治疗与多重耐药革兰阴性菌败血症新生儿的存活相关,不良反应频率中等。

研究设计与样本

  • 回顾性记录回顾研究,纳入2015年6月至2018年6月巴基斯坦卡拉奇Aga Khan大学医院新生儿重症监护室收治的153例接受黏菌素治疗的新生儿败血症患儿。

主要发现

  • 153例接受黏菌素的新生儿中,120例为培养证实的败血症,93例为MDR-GNB感染(其中84例为黏菌素敏感)。
  • 111例(72.5%)存活出院,82.6%实现微生物清除。
  • 黏菌素敏感菌感染(AOR=3.2,95%CI 2.8-4.0)和早期启动黏菌素治疗(AOR=7.2,95%CI 3.5-13.6)与更高生存率相关。
  • 胎龄增加(AOR=1.9,95%CI 1.5-3.0)、体重较高(AOR=5.4,95%CI 3.3-11.8)和晚发型败血症(AOR=4.3,95%CI 2.0-9.0)与更高生存率相关。
  • 不良反应包括肾毒性5.2%、惊厥13.7%和电解质紊乱18.3%。

关键数值与推荐

  • 黏菌素敏感菌感染的调整OR=3.2(95%CI 2.8-4.0),早期启动黏菌素治疗的调整OR=7.2(95%CI 3.5-13.6)。
  • 胎龄增加的调整OR=1.9(95%CI 1.5-3.0),体重较高的调整OR=5.4(95%CI 3.3-11.8),晚发型败血症的调整OR=4.3(95%CI 2.0-9.0)。

临床怎么用

  • 对于多重耐药革兰阴性菌败血症新生儿,黏菌素可作为治疗选择,早期启动可能改善生存。
  • 使用黏菌素期间需监测肾毒性、惊厥和电解质紊乱等不良反应。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Infections with multidrug-resistant organisms (MDROs) such as Gram-negative bacteria have high morbidity and mortality with limited treatment options. Colistin, an antibiotic active against MDRO, was rarely used due to frequent adverse effects, but its use has now been recommended among adults. In this study, we determined the efficacy of colistin for the treatment of sepsis in neonates. DESIGN/SETTING/PATIENTS/OUTCOMES: We conducted a retrospective record review of all neonates admitted to the neonatal intensive care unit of Aga Khan University Hospital, Karachi, Pakistan, between June 2015 and June 2018, who had sepsis and received colistin by intravenous, inhalation and/or intrathecal routes. Predictors of colistin efficacy, for neonatal survival and microbial clearance, were assessed using multiple logistic regression. RESULTS: 153 neonates received colistin; 120 had culture-proven sepsis; and 93 had MDR-GNB (84 colistin-sensitive). 111 (72.5%) neonates survived and were discharged from hospital; 82.6% had microbial clearance. Neonates with colistin-sensitive bacteria (adjusted OR (AOR)=3.2, 95% CI 2.8 to 4.0), and those in which colistin therapy started early (AOR=7.2, 95% CI 3.5 to 13.6) were more likely to survive. Neonates with increased gestational age (AOR=1.9, 95% CI 1.5 to 3.0), higher weight (AOR=5.4, 95% CI 3.3 to 11.8) and later onset of sepsis (AOR=4.3, 95% CI 2.0 to 9.0) had higher survival. Adverse events included nephrotoxicity in 5.2%; 13.7% developed seizures and 18.3% had electrolyte imbalance. CONCLUSIONS: Colistin therapy was associated with survival among neonates suffering from MDR-GNB sepsis. The frequency of side effects was moderate.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Ambreen G, Salat MS, Hussain K, et al. Efficacy of colistin in multidrug-resistant neonatal sepsis: experience from a tertiary care center in Karachi, Pakistan. Arch Dis Child. 2020. PMID: 32198160. doi:10.1136/archdischild-2019-318067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。